 |
29 Diseases |  |
78 Trials |
|
78 Trials |  |
3560 News |  |
| «12...33343536373839404142434445» |
- Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date, Trial primary completion date: GIMEMA LAL2116: D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 22, 2016
P2, N=60, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2019 --> Jun 2020
- Blincyto (blinatumomab) / Astellas, Amgen
Clinical: RIALTO: Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (clinicaltrials.gov) - Nov 15, 2016
P4, N=0, Available, Sponsor: Amgen
Initiation date: Jun 2016 --> Dec 2016 | Trial primary completion date: Dec 2019 --> Jun 2020 Phase classification: P=N/A --> P4
- | Blincyto (blinatumomab) / Astellas, Amgen, blinatumomab subcutaneous / Amgen
New P1 trial: A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 13, 2016
P1b, N=33, Not yet recruiting, Sponsor: Amgen
- |||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 3, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 11, 2016
P1, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=18 --> 36
- || Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 4, 2016
P1b/2, N=57, Recruiting, Sponsor: Amgen
N=18 --> 36 Trial primary completion date: Nov 2018 --> Feb 2018
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
New P2/3 trial: Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL (clinicaltrials.gov) - Sep 21, 2016
P2/3, N=332, Not yet recruiting, Sponsor: Amgen
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2016
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2018 --> Feb 2018 Not yet recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Combination therapy, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: NCI-2016-01300: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 26, 2016
P1, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 23, 2016
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2016
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2019 --> Jul 2021
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 14, 2016
P2, N=93, Completed, Sponsor: Amgen Research (Munich) GmbH
Trial primary completion date: Jul 2019 --> Jul 2021 Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Jul 5, 2016
P2, N=18, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial primary completion date: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 29, 2016
P1/2, N=146, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Sep 2018
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 23, 2016
P2, N=28, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 21, 2016
P2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 18, 2016
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Sep 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2016 --> Dec 2018 | Not yet recruiting --> Recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 13, 2016
P1b/2, N=57, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2016 --> Dec 2018 | Not yet recruiting --> Recruiting Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2019 --> Nov 2018
- Blincyto (blinatumomab) / Astellas, Amgen
New P4 trial: Administration of blinatumomab to one pediatric patient Blinatumomab használata egy gyermek betegnél (EUDRACT) - Jun 11, 2016
P4, N=1, Ongoing, Sponsor: BAZ Megyei és Egyetemi Oktató Kórház
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Jun 9, 2016
P2, N=18, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- || Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2016
P1/2, N=57, Recruiting, Sponsor: Amgen
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2019 --> Nov 2018 Trial primary completion date: Nov 2018 --> Jul 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: GIMEMA LAL2116: D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2016
P2, N=60, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 25, 2016
P3, N=405, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Nov 2018 --> Jul 2019 Trial primary completion date: Aug 2016 --> Dec 2015
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 4, 2016
P3, N=320, Recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2016 --> Dec 2015 Trial primary completion date: Oct 2018 --> Jan 2019
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 21, 2015
P1/2, N=57, Recruiting, Sponsor: Amgen
Trial primary completion date: Oct 2018 --> Jan 2019 N=39 --> 57
- |||||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Dec 4, 2015
P3, N=320, Recruiting, Sponsor: Amgen
N=39 --> 57 Not yet recruiting --> Recruiting
- |||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=146, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 15, 2015
P1/2, N=126, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 24, 2015
P3, N=405, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 22, 2015
P3, N=320, Not yet recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Initiation date: Sep 2015 --> Dec 2015
- | Blincyto (blinatumomab) / Astellas, Amgen
New P1 trial: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 6, 2015
P1, N=18, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Sep 17, 2015
P3, N=400, Recruiting, Sponsor: Amgen
Initiation date: Sep 2015 --> Dec 2015 Active, not recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open, Minimal residual disease: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (clinicaltrials.gov) - Sep 16, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Sep 15, 2015
P3, N=400, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=39, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial primary completion date: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=126, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2015
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2016 --> Sep 2017 Suspended --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial, Minimal residual disease: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (clinicaltrials.gov) - May 29, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 9, 2015
P1/2, N=39, Not yet recruiting, Sponsor: Amgen
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 20, 2015
P3, N=320, Not yet recruiting, Sponsor: Amgen
- Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 9, 2015
P3, N=598, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Feb 19, 2015
P3, N=400, Recruiting, Sponsor: Amgen
Recruiting --> Suspended Trial primary completion date: May 2016 --> Aug 2016
- Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 28, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Alcantara: Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 26, 2015
P2, N=45, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jan 22, 2015
P2, N=225, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Oct 2013
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jan 7, 2015
P2, N=36, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Trial primary completion date: Jun 2014 --> Oct 2013 N=25 --> 36
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion, Trial initiation date, Trial primary completion date, Minimal residual disease: Phase II Study of the BiTE (clinicaltrials.gov) - Jan 7, 2015
P2, N=21, Completed, Sponsor: Amgen Research (Munich) GmbH
N=25 --> 36 Active, not recruiting --> Completed | Initiation date: Oct 2007 --> Jan 2008 | Trial primary completion date: Dec 2009 --> Sep 2009
- | Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 19, 2014
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Initiation date: Oct 2007 --> Jan 2008 | Trial primary completion date: Dec 2009 --> Sep 2009 Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014
- Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014 Initiation date: Aug 2014 --> Jan 2015
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change, Trial primary completion date: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 3, 2014
P2, N=225, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Initiation date: Aug 2014 --> Jan 2015 N=180 --> 225 | Trial primary completion date: Dec 2013 --> Jun 2014